| 產(chǎn)品編號 | bsm-60307R |
| 英文名稱 | CDKN2A/p14ARF Recombinant Rabbit mAb |
| 中文名稱 | 抑癌基因p14重組兔單抗 |
| 別 名 | cyclin-dependent kinase inhibitor 2A; CDK4I; p16-INK4; p16-INK4a; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A, isoform 1; Cyclin dependent kinase inhibitor 2A(p16, inhibits CDK4); cell cycle inhibitor; cyclin-dependent kinase inhibitor 2a p16Ink4a; cell cycle regulator; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 2; Cdkn2a; Arf; INK4A; MTS1; p16; p16Cdkn2a; p19ARF; CD2A2_HUMAN. |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 染色質(zhì)和核信號 干細(xì)胞 細(xì)胞周期蛋白 轉(zhuǎn)錄調(diào)節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | F2K1 |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,ICC/IF=1:50
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 14 kDa |
| 檢測分子量 | |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human P14ARF |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]. SWISS: P42771 Gene ID: 1029 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with CDKN2A/p14ARF monoclonal antibody, unconjugated (bsm-60307R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
(UPPER PANEL) 4% Paraformaldehyde-fixed Hela (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (CDKN2A/P14arf) monoclonal Antibody, unconjugated (bsm-60307R) 1:50, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-60295G-FITC) at 37°C for 90 min.
(LOWER PANEL) DAPI (blue, C02-04002) was used to stain the cell nuclei.
|
